Seminars in Nuclear Medicine
Volume 33, Issue 2 , Pages 105-113 , April 2003

Imaging studies in movement disorders

References 

  1. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology. 1967;17:427–442
  2. Bernheimer H, Birkmayer W, Hornykiewicz O, et al.  Brain dopamine and the syndromes of parkinson and huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973;20:415–455
  3. Brooks DJ. PET and SPECT studies in parkinson's disease. Baillieres Clin Neurol. 1997;6:69–87
  4. Mozley PD, Schneider JS, Acton PD, et al.  Binding of [99mtc]trodat-1 to dopamine transporters in patients with parkinson's disease and in healthy volunteers. J Nucl Med. 2000;41:584–589
  5. Brooks DJ. Morphological and functional imaging studies on the diagnosis and progression of parkinson's disease. J Neurol. 2000;247(Suppl 2):II11–II18
  6. Marek K, Innis R, van Dyck C, et al.  [123-I]beta-CIT SPECT imaging assessment of the rate of parkinson's disease progression. Neurology. 2001;57:2089–2094
  7. Seibyl JP, Marek KL, Quinlan D, et al.  Decreased single-photon emission computed tomographic [123-I]beta-CIT striatal uptake correlates with symptom severity in parkinson's disease. Ann Neurol. 1995;138:589–598
  8. Benamer HT, Patterson J, Wyper DJ, et al.  Correlation of parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord. 2000;15:692–698
  9. Fischman AJ, Bonab AA, Babich JW, et al.  Rapid detection of parkinson's disease by SPECT with altropane: A selective ligand for dopamine transporters. Synapse. 1998;29:128–141
  10. Ichise M, Kim YJ, Ballinger JR, et al.  SPECT imaging of pre- and postsynaptic dopaminergic alterations in 1-dopa-untreated PD. Neurology. 1999;52:1206–1214
  11. Frey KA, Koeppe RA, Kilbourn MR, et al.  Presynaptic monoaminergic vesicles in parkinson's disease and normal aging. Ann Neurol. 1996;40:873–884
  12. Brooks DJ. PET studies and motor complications in Parkinson's disease. Trends Neurosci. 2000;23:S101–S108
  13. Brooks DJ. Positron emission tomography studies in movement disorders. Neurosurg Clin N Am. 1998;9:263–282
  14. Morrish PK, Sawle GV, Brooks DJ. The rate of progression of Parkinson's disease. A longitudinal [18F]dopa PET study. Adv Neurol. 1996;69:427–431
  15. Nurmi E, Ruottinen HM, Kaasinen V, et al.  Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [18F]CFT. Ann Neurol. 2000;47:804–808
  16. Hall H, Halldin C, Guilloteau D, et al.  Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2i. Neuroimage. 1999;9:108–116
  17. Madras BK, Gracz LM, Fahey MA, et al.  Altropane, a SPECT or PET imaging probe for dopamine neurons: Iii. Human dopamine transporter in postmortem normal and parkinson's diseased brain. Synapse. 1998;29:116–127
  18. Harrington KA, Augood SJ, Kingsbury AE, et al.  Dopamine transporter (DAT) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease. Brain Res Mol Brain Res. 1996;36:157–162
  19. Ishikawa T, Dhawan V, Kazumata K, et al.  Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-fdopa/PET. J Nucl Med. 1996;37:1760–1765
  20. Tissingh G, Bergmans P, Winogrodzka A, et al.  Nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-fdopa/PET. J Nucl Med. 1997;38:1271–1272
  21. Ito Y, Fujita M, Shimada S, et al.  Comparison between the decrease of dopamine transporter and that of 1-dopa uptake for detection of early to advanced stage of parkinson's disease in animal models. Synapse. 1999;31:178–185
  22. Marek K, Seibyl J. Techsight. Imaging. A molecular map for neurodegeneration. Science. 2000;289:409–411
  23. Lavalaye J, Booij J, Reneman L, et al.  Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPECT in healthy volunteers. Eur J Nucl Med. 2000;27:867–869
  24. Booij J, Tissingh G, Boer GJ, et al.  [1231]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatr. 1997;62:133–140
  25. van Dyck CH, Seibyl JP, Malison RT, et al.  Age-related decline in dopamine transporters: Analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatr. 2002;10:36–43
  26. Neumeyer JL, Wang SY, Milius RA, et al.  [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: High-affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem. 1991;34:3144–3146
  27. Kung MP, Stevenson DA, Plossl K, et al.  [99mTc]trodat-I: A novel technetium-99m complex as a dopamine transporter imaging agent. Eur J Nucl Med. 1997;24:372–380
  28. Madras BK, Gracz LM, Meltzer PC, et al.  Altropane, a SPECT or PET imaging probe for dopamine neurons: Ii. Distribution to dopamine-rich regions of primate brain. Synapse. 1998;29:105–115
  29. Seibyl JP, Marek K, Sheff K, et al.  Iodine-123-beta-CIT and iodine-123-FP-CIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med. 1998;39:1500–1508
  30. Booij J, Speelman JD, Horstink MW, et al.  The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med. 2001;28:266–272
  31. Huang WS, Lin SZ, Lin JC, et al.  Evaluation of early-stage Parkinson's disease with 99mtc-trodat-1 imaging. J Nucl Med. 2001;42:1303–1308
  32. Vander Borght T, Kilbourn M, Desmond T, et al.  The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol. 1995;294:577–583
  33. Hughes AJ, Daniel SE, Kilford L, et al.  Accuracy of clinical diagnosis of idiopathic parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatr. 1992;55:181–184
  34. Hughes AJ, Ben-Shlomo Y, Daniel SE, et al.  What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study. Neurology. 2001;57:S34–S38
  35. Calne DB. Diagnosis and treatment of Parkinson's disease. Hosp Pract (Off Ed). 1995;30:83–86 89
  36. Brooks DJ. The early diagnosis of Parkinson's disease. Ann Neurol. 1998;44:S10–S18
  37. Wolters EC, Francot C, Bergmans P, et al.  Preclinical (premotor) Parkinson's disease. J Neurol. 2000;247(Suppl 2):II103–II109
  38. Parkinson's Study Group . A multicenter assessment of dopamine transporter imaging with Dopascan/SPECT in Parkinsonism. Neurology. 2000;55:1540–1547
  39. Fernandez HH, Friedman JH, Fischman AJ, et al.  Is altropane SPECT more sensitive to fluorodopa PET for detecting early parkinson's disease?. Med Sci Monit. 2001;7:1339–1343
  40. Marek KL, Seibyl JP, Zoghbi SS, et al.  [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-parkinson's disease. Neurology. 1996;46:231–237
  41. Staffen W, Mair A, Unterrainer J, et al.  [123I] beta-CIT binding and SPET compared with clinical diagnosis in parkinsonism. Nucl Med Commun. 2000;21:417–424
  42. Benamer TS, Patterson J, Grosset DG, et al.  Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group. Mov Disord. 2000;15:503–510
  43. Tissingh G, Booij J, Bergmans P, et al.  Iodine-123-n-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive parkinson's disease. J Nucl Med. 1998;39:1143–1148
  44. Brucke T, Asenbaum S, Pirker W, et al.  Measurement of the dopaminergic degeneration in parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl. 1997;50:9–24
  45. Asenbaum S, Pirker W, Angelberger P, et al.  [123I]beta-CIT and SPECT in essential tremor and parkinson's disease. J Neural Transm. 1998;105:1213–1228
  46. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed parkinson's disease. Age Ageing. 1999;28:99–102
  47. Varrone A, Marek KL, Jennings D, et al.  [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in parkinson's disease and multiple system atrophy. Mov Disord. 2001;16:1023–1032
  48. Messa C, Volonte MA, Fazio F, et al.  Differential distribution of striatal [123I]beta-CIT in parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography. Eur J Nucl Med. 1998;25:1270–1276
  49. Brucke T, Djamshidian S, Bencsits G, et al.  SPECT and PET imaging of the dopaminergic system in parkinson's disease. J Neurol. 2000;247(Suppl 4):IV/2–IV/7
  50. Staffen W, Mair A, Unterrainer J, et al.  Measuring the progression of idiopathic parkinson's disease with [123I] beta-CIT SPECT. J Neural Transm. 2000;107:543–552
  51. Morrish PK, Rakshi JS, Bailey DL, et al.  Measuring the rate of progression and estimating the preclinical period of parkinson's disease with [18f]dopa PET. J Neurol Neurosurg Psychiatr. 1998;64:314–319
  52. Brooks DJ. Monitoring neuroprotection and restorative therapies in parkinson's disease with PET. J Neural Transm Suppl. 2000;125–137
  53. Parkinson study group . A randomized controlled trial comparing pramipexole with levodopa in early parkinson's disease: Design and methods of the CALM-PD study. Clin Neuropharmacol. 2000;23:34–44
  54. Parkinson study group . Pramipexole vs levodopa as initial treatment for parkinson disease: A randomized controlled trial. JAMA. 2000;284:1931–1938
  55. Kish SJ, Kalasinsky KS, Derkach P, et al.  Striatal dopaminergic and serotonergic markers in human heroin users. Neuropsychopharmacology. 2001;24:561–567
  56. Volkow ND, Chang L, Wang GJ, et al.  Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci. 2001;21:9414–9418
  57. Lee CS, Samii A, Sossi V, et al.  In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in parkinson's disease. Ann Neurol. 2000;47:493–503
  58. Donovan DM, Miner LL, Perry MP, et al.  Cocaine reward and MPTP toxicity: Alteration by regional variant dopamine transporter overexpression. Brain Res Mol Brain Res. 1999;73:37–49
  59. Murer MG, Dziewczapolski G, Menalled LB, et al.  Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol. 1998;43:561–575
  60. Wilson JM, Kish SJ. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci. 1996;16:3507–3510
  61. Innis RB, Marek KL, Sheff K, et al.  Effect of treatment with 1-dopa/carbidopa or 1-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord. 1999;14:436–442
  62. Marek K, Seibyl J, Shoulson I, et al.  Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on parkinson disease progression. JAMA. 2002;287:1653–1661
  63. Ahlskog JE, Uitti RJ, O'Connor MK, et al.  The effect of dopamine agonist therapy on dopamine transporter imaging in parkinson's disease. Mov Disord. 1999;14:940–946
  64. Guttman M, Burkholder J, Kish SJ, et al.  [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive parkinson's disease: Implications for the symptomatic threshold. Neurology. 1997;48:1578–1583
  65. Nurmi E, Bergman J, Eskola O, et al.  Reproducibility and effect of levodopa on dopamine transporter function measurements: A [18F]CFT PET study. J Cereb Blood Flow Metab. 2000;20:1604–1609
  66. Chan GL, Holden JE, Stoessl AJ, et al.  Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects. J Nucl Med. 1999;40:283–289
  67. Booij J, Habraken JB, Bergmans P, et al.  Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with parkinson's disease. J Nucl Med. 1998;39:1879–1884
  68. Seibyl JP, Marek K, Sheff K, et al.  Test/retest reproducibility of iodine-123-beta CIT SPECT brain measurement of dopamine transporters in parkinson's patients. J Nucl Med. 1997;38:1453–1459
  69. Vingerhoets FJ, Snow BJ, Schulzer M, et al.  Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nucl Med. 1994;35:18–24

☆ Address reprint requests to John P. Seibyl, MD, Institute for Neurodegenerative Disorders, 60 Temple Street, Ste 8B, New Haven CT 06510.

☆☆ 0001-2998/03/3302-0006$30.00/0

PII: S0001-2998(03)70015-4

doi: 10.1053/snuc.2003.127303

Seminars in Nuclear Medicine
Volume 33, Issue 2 , Pages 105-113 , April 2003

Article Tools

* Image Usage & Resolution